DM
ELEV

Deerfield Management’s Elevation Oncology ELEV Stock Holding History

Deerfield Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,381,416
Closed -$2.1M – 96
2023
Q2 		$2.1M Buy
+1,381,416
New +$3.64M 0.04% 84

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Deerfield Management's ELEV Position: Q3 2023 in Review

Deerfield Management sold out of Elevation Oncology (ELEV) in Q3 2023, closing a stake of 1,381,416 shares — an estimated $2.1M sold.

Deerfield Management first reported a position in ELEV in Q2 2023 and held it in 1 quarter. The position peaked at $2.1M in Q2 2023. 41 funds tracked by Wall St. Rank hold ELEV as of Q3 2023.

  • Deerfield Management reported no remaining Elevation Oncology position as of Q3 2023 after selling out during the quarter.
  • Deerfield Management sold 1,381,416 Elevation Oncology shares in Q3 2023, an estimated $2.1M.
  • Deerfield Management first reported a position in Elevation Oncology in Q2 2023 and held it in 1 quarter.
  • Deerfield Management's Elevation Oncology position peaked at $2.1M in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2023.

Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.